Last reviewed · How we verify
clotrimazole vaginal tablets
Clotrimazole disrupts fungal cell membrane integrity by inhibiting ergosterol synthesis, leading to cell death.
Clotrimazole disrupts fungal cell membrane integrity by inhibiting ergosterol synthesis, leading to cell death. Used for Vulvovaginal candidiasis.
At a glance
| Generic name | clotrimazole vaginal tablets |
|---|---|
| Also known as | clotrimazole vaginal tablets（Bayer） |
| Sponsor | Peking University Shenzhen Hospital |
| Drug class | Imidazole antifungal |
| Target | Lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Clotrimazole is an imidazole antifungal that inhibits the fungal cytochrome P450 enzyme lanosterol 14α-demethylase, blocking the conversion of lanosterol to ergosterol. This disrupts the structural integrity of the fungal cell membrane, causing leakage of cellular contents and fungal cell death. It is effective against a broad spectrum of fungi and is commonly used topically for vaginal candidiasis.
Approved indications
- Vulvovaginal candidiasis
Common side effects
- Vaginal irritation or burning
- Vulvar irritation
- Abdominal cramping
- Headache
Key clinical trials
- Study of Lactobacillus in Adjuvant Treatment of RVVC (PHASE4)
- Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis (PHASE2, PHASE3)
- Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth (PHASE4)
- A Protocol for the Role of Fractional CO2 Laser in Consolidation Treatment of Recurrent Vulvovaginal Candidiasis (NA)
- Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis (PHASE3)
- Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis (PHASE4)
- Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis (PHASE4)
- Comparative Efficacy of Ovule vs Tablet (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clotrimazole vaginal tablets CI brief — competitive landscape report
- clotrimazole vaginal tablets updates RSS · CI watch RSS
- Peking University Shenzhen Hospital portfolio CI